AU595221B2 - Fusion proteins, a process for their preparation and their use - Google Patents

Fusion proteins, a process for their preparation and their use

Info

Publication number
AU595221B2
AU595221B2 AU60565/86A AU6056586A AU595221B2 AU 595221 B2 AU595221 B2 AU 595221B2 AU 60565/86 A AU60565/86 A AU 60565/86A AU 6056586 A AU6056586 A AU 6056586A AU 595221 B2 AU595221 B2 AU 595221B2
Authority
AU
Australia
Prior art keywords
sequence
amino acids
genetically codable
genetically
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU60565/86A
Other languages
English (en)
Other versions
AU6056586A (en
Inventor
Paul Habermann
Siegfried Stengelin
Friedrich Wengenmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU6056586A publication Critical patent/AU6056586A/en
Application granted granted Critical
Publication of AU595221B2 publication Critical patent/AU595221B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU60565/86A 1985-07-27 1986-07-25 Fusion proteins, a process for their preparation and their use Expired AU595221B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3526995 1985-07-27
DE19853526995 DE3526995A1 (de) 1985-07-27 1985-07-27 Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung

Publications (2)

Publication Number Publication Date
AU6056586A AU6056586A (en) 1987-01-29
AU595221B2 true AU595221B2 (en) 1990-03-29

Family

ID=6276985

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60565/86A Expired AU595221B2 (en) 1985-07-27 1986-07-25 Fusion proteins, a process for their preparation and their use

Country Status (18)

Country Link
EP (1) EP0211299B1 (de)
JP (1) JPH07113040B2 (de)
KR (1) KR950000299B1 (de)
AT (1) ATE50596T1 (de)
AU (1) AU595221B2 (de)
CA (1) CA1336329C (de)
DE (2) DE3526995A1 (de)
DK (1) DK172618B1 (de)
ES (1) ES2000278A6 (de)
FI (1) FI86887C (de)
GR (1) GR861957B (de)
HU (1) HU197356B (de)
IE (1) IE59127B1 (de)
IL (1) IL79522A (de)
NO (1) NO175640C (de)
NZ (1) NZ216967A (de)
PT (1) PT83065B (de)
ZA (1) ZA865556B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738541A1 (de) * 1987-11-13 1989-05-24 Hoechst Ag Verfahren zur isolierung und reinigung von hirudin
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
EP0237338B1 (de) * 1986-03-12 1992-09-23 IMCERA Group Inc. Hybride Expressionsvektoren, deren Herstellung und Verwendungen
EP0371041A1 (de) * 1987-06-24 1990-06-06 Novo Nordisk A/S Verfahren für die herstellung eines proteins oder polypeptides, dns-sequenz, die dieses polypeptid kodiert, mikroorganismus, der diese dns-sequenz beinhaltet, sowie das polypeptid und seine verwendung als pharmazeutisches präparat
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
US5227293A (en) * 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
IL95495A (en) * 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (de) * 1989-12-22 1991-06-27 Basf Ag Verfahren zur herstellung von hirudin
DE59711533D1 (de) 1996-07-26 2004-05-27 Aventis Pharma Gmbh Insulinderivate mit erhöhter Zinkbindung
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2009066320A2 (en) 2007-09-21 2009-05-28 Cadila Healthcare Limited Fusion protein systems suitable for high expression of peptides
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5523686A (en) * 1985-03-25 1986-10-02 Wellcome Foundation Limited, The Epidermal growth factor production and method to depilate animals such as sheep
AU5668086A (en) * 1985-03-18 1986-10-13 Genelabs Incorporated Hybrid genes (eg. IG's & MHC proteins) via lambda library andplasmid casette vector
AU5669086A (en) * 1985-04-08 1986-11-05 Genetic Systems Corporation Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA802992B (en) * 1979-06-01 1981-10-28 Univ California Human pre-growth hormone
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5668086A (en) * 1985-03-18 1986-10-13 Genelabs Incorporated Hybrid genes (eg. IG's & MHC proteins) via lambda library andplasmid casette vector
AU5523686A (en) * 1985-03-25 1986-10-02 Wellcome Foundation Limited, The Epidermal growth factor production and method to depilate animals such as sheep
AU5669086A (en) * 1985-04-08 1986-11-05 Genetic Systems Corporation Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav

Also Published As

Publication number Publication date
FI863041A (fi) 1987-01-28
DK355486A (da) 1987-01-28
KR950000299B1 (ko) 1995-01-13
EP0211299A3 (en) 1988-06-01
DE3669175D1 (de) 1990-04-05
DE3526995A1 (de) 1987-02-05
FI863041A0 (fi) 1986-07-24
JPS6229600A (ja) 1987-02-07
DK172618B1 (da) 1999-03-01
FI86887B (fi) 1992-07-15
JPH07113040B2 (ja) 1995-12-06
NO863000D0 (no) 1986-07-25
PT83065A (de) 1986-08-01
IE861977L (en) 1987-01-27
ES2000278A6 (es) 1988-02-01
EP0211299B1 (de) 1990-02-28
IE59127B1 (en) 1994-01-12
IL79522A (en) 1991-08-16
NZ216967A (en) 1988-08-30
EP0211299A2 (de) 1987-02-25
HUT43629A (en) 1987-11-30
NO175640B (de) 1994-08-01
IL79522A0 (en) 1986-10-31
GR861957B (en) 1986-11-25
PT83065B (pt) 1989-02-28
DK355486D0 (da) 1986-07-25
FI86887C (fi) 1992-10-26
KR870001312A (ko) 1987-03-13
NO863000L (no) 1987-01-28
ZA865556B (en) 1987-03-25
CA1336329C (en) 1995-07-18
ATE50596T1 (de) 1990-03-15
AU6056586A (en) 1987-01-29
HU197356B (en) 1989-03-28
NO175640C (no) 1994-11-09

Similar Documents

Publication Publication Date Title
AU595221B2 (en) Fusion proteins, a process for their preparation and their use
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
IL81018A (en) Fusion proteins comprising small fragments of human interleukin-2 as ballast,process for its preparation and genes,vectors and transformed host containing said fragments and used in the process
AU561343B2 (en) Human immune interferon by recombinant dna
FI853056L (fi) Menetelmä hirudiinin vaikutusta omaavan polypeptidin valmistamiseksi
DE68922917D1 (de) KEX2-Endoprotease und Verfahren zu ihrer Herstellung.
ES8603574A1 (es) "procedimiento de tecnologia genetica para preparar secuen- cias parciales del gamma-interferon de humano".
FI880017A0 (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
EP0111814A3 (de) Klonierung und Expression von nucleotiden Sequenzen die für Rinderwachstumshormon kodieren
ATE89317T1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
AU9026691A (en) New human recombinant gamma interferon
EP0330700A4 (de) Menschlicher Prourokinase ähnliches Polypeptid.
EP0222279A3 (en) Production of active proteins containing cystine residues
JPS6438099A (en) Fused protein or dihydrofolate reductase and bradykinin
IE872531L (en) Preparation of salmon calcitonin by genetic engineering, and¹means for carrying out this process
CA1267086C (en) METHOD OF ADMINISTRATION OF EAR DIURETIC PEPTIDES
FI934079A (fi) Menetelmä fuusioproteiinin valmistamiseksi